<DOC>
	<DOCNO>NCT02740998</DOCNO>
	<brief_summary>Despite many year research , controversy persist whether hormonal contraception promotes HIV acquisition . A number observational study depot medroxyprogesterone acetate ( DMPA ) injection show increase HIV risk evidence increase risk oral contraceptive pill . There human study currently publish impact levonorgestrel intrauterine device ( LNG IUD ) HIV transmission risk minimal data effect etonogestrel subdermal implant ( ESI ) risk HIV acquisition . Establishing whether highly effective contraceptive increase risk HIV infection would far-reaching public health implication , particularly area high HIV prevalence sub-Saharan Africa , injectable contraception account nearly half contraceptive use . Perturbations normal vaginal microbiota , community microorganism inhabit vaginal body niche , long know affect risk transmission HIV . Studies show alter vaginal microbiota DMPA injection preserve vaginal microbiota LNG IUD , study compare method head-to-head use culture-independent sequencing methodology . The investigator propose prospective pilot study evaluate impact different long-acting progestin contraceptive formulation vaginal microbiome . Specifically , investigator aim identify compare metagenomics profile associate DMPA , LNG IUD , ESI contraceptive use community analysis vaginal swab sample woman collect longitudinally contraceptive method initiation . The investigator hypothesize DMPA increase community diversity vaginal microbiota , whereas LNG IUD ESI affect balance microorganism vagina . Women plan initiate DMPA , LNG IUD , ESI contraception well control seek contraception recruit study Boston Medical Center ( BMC ) , tertiary care center racially socioeconomically diverse patient population . Women longitudinal follow-up self-sampling vagina sexually transmit infection test metagenomics analysis method initiation , 2-3 month , 6 month . Establishing safe long-acting progestin contraceptive alternative promote effective contraception use low rate HIV acquisition worldwide .</brief_summary>
	<brief_title>Long-Acting Progestin Contraception Vaginal Microbiome</brief_title>
	<detailed_description>Women age 18-45 initiate long-acting progestin contraception enrol routine office visit family plan clinic institution . Enrollment begin April 2016 stop 6 month allow longitudinal follow-up analysis . For pilot study , total 30 long-acting progestin contraceptive initiator 10 subject method group ( DMPA , LNG IUD , ESI ) 5 age-matched , control seek tubal sterilization select longitudinal STI screen vaginal sample microbiome analysis . After consent obtain , trained staff interview subject use brief sociodemographic/habits questionnaire include question age , race , body mass index , smoke status , history sexually transmit infection yeast vaginitis , weekly frequency coitus , number lifetime sexual partner . Subjects instruct self-sample vagina three timepoints : 1 ) method initiation , 2 ) 2-3 month later , 3 ) 6 month later . Self-collected vaginal swab specimen assay Trichomonas vaginalis , Chlamydia trachomatis , Neisseria gonorrhoeae use DNA amplification clinical lab . Microbiome sample collect timepoint analyze compare initiation sample detect longitudinal difference .</detailed_description>
	<mesh_term>Sexually Transmitted Diseases</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Inclusion criterion Women age 1840 elect start longacting progestin contraceptive opt tubal sterilization . Our site enroll 18 patient total : 5 DMPA ; 5 Mirena IUD , 5 Nexplanon , 23 tubal ligations/Essures ( control ) Exclusion criterion NonEnglishspeaking without translator Current recent ( within past 3 month ) use hormonal contraception Currently menstruate Vaginal intercourse within 48 hour visit Known suspect pregnancy , pregnancy within past 6 week . Use progestin method primary indication contraception ( e.g . pelvic pain , menorrhagia ) Current STI vaginitis ( yeast BV ) Tampon usage Regular douching Chronic antibiotic use within past 4 week HIV positive Immunosuppressive therapy ( organ transplant , chemotherapy )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Microbiome</keyword>
	<keyword>Progestin</keyword>
	<keyword>Long-acting contraception</keyword>
</DOC>